BRIEF published on 08/22/2024 at 18:05, 1 year 7 months ago ABIONYX Pharma : Bilan du 1er semestre 2024 Chiffre D'affaires Biotechnologie Trésorerie Levée De Fonds ABIONYX Pharma
BRIEF published on 08/22/2024 at 18:05, 1 year 7 months ago ABIONYX Pharma: Review of the first half of 2024 Biotechnology Fundraising Treasury Turnover ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 1 year 7 months ago Informations privilégiées / Autres communiqués ABIONYX Pharma publie sa position de trésorerie du 1er semestre 2024 avec un chiffre d’affaires consolidé de 2,4 M€. Levée de fonds de 3,4 M€ pour renforcer la trésorerie Chiffre D'affaires Biotechnologie Trésorerie Levée De Fonds ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 1 year 7 months ago Inside Information / Other news releases ABIONYX Pharma reports €2.4m sales and €5.3m cash position for H1 2024, focused on innovative therapies. Raised €3.4m for sepsis program in the US Sales Cash Position Innovative Therapies ABIONYX Pharma Sepsis
BRIEF published on 07/01/2024 at 09:27, 1 year 8 months ago ABIONYX Successfully Completes €3.4 Million Capital Increase Capital Increase Biotech Shares And Warrants ABIONYX Sepsis Development
BRIEF published on 07/01/2024 at 09:27, 1 year 8 months ago ABIONYX finalise avec succès une augmentation de capital de 3,4 millions d'euros Augmentation De Capital Actions Et Bons De Souscription Biotechnologies ABIONYX Développement De La Septicémie
PRESS RELEASE published on 07/01/2024 at 09:22, 1 year 8 months ago Inside Information / Other news releases ABIONYX successfully completes a capital increase of c.€3.4 million through the issuance of shares with warrants. The fundraising aims to strengthen the company's cash position for its development in sepsis and the United States Fundraising Capital Increase Sepsis ABIONYX Shares With Warrants
BRIEF published on 06/27/2024 at 19:27, 1 year 8 months ago ABIONYX Pharma Achieves Unanimous Approval at Combined General Meeting Shareholders Biotech General Meeting Resolutions ABIONYX Pharma
BRIEF published on 06/27/2024 at 19:27, 1 year 8 months ago ABIONYX Pharma obtient l'approbation unanime de l'Assemblée Générale Mixte Actionnaires Assemblée Générale Resolutions Biotechnologies ABIONYX Pharma
PRESS RELEASE published on 06/27/2024 at 19:22, 1 year 8 months ago Inside Information / Other news releases ABIONYX Pharma announces unanimous approval of all resolutions at its Combined General Meeting. Shareholders renew mandates and approve buyback program Shareholders Buyback Program Renewal Combined General Meeting ABIONYX Pharma
Published on 03/24/2026 at 10:10, 4 minutes ago BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform
Published on 03/24/2026 at 08:01, 2 hours 13 minutes ago Star Copper Confirms Copper Creek Mineralization
Published on 03/24/2026 at 07:00, 3 hours 14 minutes ago Panther Minerals Earns In Under Rubidium Ridge Project Option
Published on 03/24/2026 at 07:00, 3 hours 14 minutes ago Panther Completes Acquisition of Rubidium Ridge Project
Published on 03/24/2026 at 10:05, 8 minutes ago Chaucer and Ceto launch Lloyd's marine MGA, integrating real-time vessel data into underwriting
Published on 03/24/2026 at 10:00, 13 minutes ago MIG Capital Continues Successful Course in 2025 Despite a Challenging Market Environment
Published on 03/24/2026 at 10:00, 13 minutes ago Best of m:access 2026: Opportunities for investors in the small and mid-cap segment
Published on 03/24/2026 at 10:00, 14 minutes ago REPLOID is growing its team and creating space for further growth and innovation
Published on 03/24/2026 at 09:21, 52 minutes ago More than 3,000 GHG credits successfully processed: Customers benefit from the services of the Allane Mobility Group
Published on 03/24/2026 at 07:45, 2 hours 29 minutes ago François Jackow’s appointment as a Board member will be submitted to the Annual General Meeting on May 7, 2026
Published on 03/24/2026 at 07:45, 2 hours 29 minutes ago La nomination de François Jackow en tant que membre du Conseil d’administration sera soumise à l’Assemblée générale du 7 mai 2026
Published on 03/24/2026 at 07:30, 2 hours 44 minutes ago Gimv secures new EUR 400 million revolving credit facility to support accelerated growth ambitions
Published on 03/24/2026 at 07:30, 2 hours 44 minutes ago Gimv verzekert zich van een nieuwe Revolving Credit Facility van EUR 400 miljoen ter ondersteuning van de versnelde groeiambities
Published on 03/23/2026 at 19:08, 15 hours 5 minutes ago Reporting on share buyback transactions carried out between March 16 and March 20, 2026
